Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04130919
Registration number
NCT04130919
Ethics application status
Date submitted
16/10/2019
Date registered
18/10/2019
Date last updated
24/08/2022
Titles & IDs
Public title
Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis
Query!
Scientific title
A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis
Query!
Secondary ID [1]
0
0
2019-001430-33
Query!
Secondary ID [2]
0
0
GS-US-365-4237
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Falcon
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ulcerative Colitis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tilpisertib
Treatment: Drugs - Placebo
Experimental: Tilpisertib 300 mg - Participants will receive blinded tilpisertib 300 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
Experimental: Tilpisertib 100 mg - Participants will receive blinded tilpisertib 100 mg for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
Placebo Comparator: Placebo - Participants will receive blinded tilpisertib matching placebo for up to 10 weeks. An efficacy assessment will be performed at Week 10. Participants who achieve MCS response will continue on the blinded treatment for up to 50 weeks.
Experimental: Open-label Tilpisertib 300 mg - Based on the efficacy assessment results at Week 10, participants who do not achieve MCS response will have the option to receive open-label tilpisertib 300 mg for up to 50 weeks.
Treatment: Drugs: Tilpisertib
Tablets administered orally once daily
Treatment: Drugs: Placebo
Tablets administered orally once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Achieved Clinical Remission Per Modified Mayo Clinic Score (MCS) at Week 10
Query!
Assessment method [1]
0
0
The modified MCS is a scoring system for assessment of ulcerative colitis (UC) activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 or more stools more than normal), and physician's global assessment (PGA) (range: 0 to 3, where 0 = normal and 3 = severe disease). Total score for MCS ranges from 0 to 12 (sum of all subscores), with higher scores indicating higher disease activity. Clinical remission per modified MCS is defined as stool frequency subscore = 1 and not greater than baseline, rectal bleeding subscore of 0, and endoscopic subscore = 1 at Week 10.
Query!
Timepoint [1]
0
0
Week 10
Query!
Secondary outcome [1]
0
0
Percentage of Participants Who Achieved Endoscopic Response at Week 10
Query!
Assessment method [1]
0
0
Endoscopic response was defined as an endoscopic subscore of = 1 at Week 10. Endoscopic subscore is a part of the modified MCS which is a scoring system for assessment of UC activity. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, lack of vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration).
Query!
Timepoint [1]
0
0
Week 10
Query!
Secondary outcome [2]
0
0
Percentage of Participants Who Achieved MCS Response at Week 10
Query!
Assessment method [2]
0
0
The modified MCS is a scoring system for assessment of UC activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 or more stools more than normal), and PGA (range: 0 to 3, where 0 = normal and 3 = severe disease). Total score for MCS ranges from 0 to 12 (sum of all subscores), with higher scores indicating higher disease activity. MCS response is defined as a decrease from baseline of = 3 points and at least 30% in MCS, in addition to a = 1 point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore = 1 at Week 10.
Query!
Timepoint [2]
0
0
Week 10
Query!
Secondary outcome [3]
0
0
Percentage of Participants Who Achieved MCS Remission at Week 10
Query!
Assessment method [3]
0
0
The modified MCS is a scoring system for assessment of UC activity and is composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease [spontaneous bleeding, ulceration]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 or more stools more than normal), and PGA (range: 0 to 3, where 0 = normal and 3 = severe disease). Total score for MCS ranges from 0 to 12 (sum of all subscores), with higher scores indicating higher disease activity. MCS remission is defined as a MCS score of = 2 and no individual subscore > 1 at Week 10.
Query!
Timepoint [3]
0
0
Week 10
Query!
Secondary outcome [4]
0
0
Percentage of Participants Who Achieved Histologic Remission Based Upon the Geboes Scale at Week 10
Query!
Assessment method [4]
0
0
Geboes histologic remission was assessed using the Geboes histologic scores to identify histologic changes in ulcerative colitis. Possible scores are Grade 0:Architectural changes(0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1:Chronic inflammatory infiltrate(1.0=No increase to 1.3=Marked increase);Grade 2A:Eosinophils in lamina propria(2A.0=No increase to 2A.3-=Marked increase; Grade 2B:Neutrophils in lamina propria(2B.0= No increase to 2B.3=Marked increase);Grade 3:Neutrophils in epithelium (3.0=None to 3.3=>50% crypts involved);Grade 4:Crypt destruction(4.0=none to 4.3=Unequivocal crypt destruction),and Grade 5:Erosions and ulcerations:(5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue). Histologic remission defined as having Grade 0 of = 0.3, Grade 1 of = 1.1, Grade 2a of = 2A.3, Grade 2b of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Geboes score ranges from 0 to 5.4. Lower values indicate better outcome.
Query!
Timepoint [4]
0
0
Week 10
Query!
Secondary outcome [5]
0
0
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [5]
0
0
Treatment-emergent adverse events (TEAEs) for the Blinded Treatment phase are either defined as AEs with an onset date on or after the Blinded Treatment phase study drug start date and no later than 30 days after permanent discontinuation of the Blinded Treatment phase study drug if no Open-label Treatment phase study drug was taken, or any AEs with an onset date on or after the Blinded Treatment phase study drug start date and before the Open-label Treatment phase study drug start date if Open-label Treatment phase study drug was taken and/or any AEs leading to premature discontinuation of Blinded Treatment phase study drug. TEAEs for the Open-label Treatment phase are either defined as AEs with an onset date on or after the Open-label Treatment phase study drug start date and no later than 30 days after permanent discontinuation of the Open-lab Treatment phase study drug and/or any AEs leading to premature discontinuation of Open-label Treatment phase study drug.
Query!
Timepoint [5]
0
0
Blinded Treatment phase: First dose date up to 50.6 weeks plus 30 days; Open-label phase: First dose date up to 50.7 weeks plus 30 days
Query!
Secondary outcome [6]
0
0
Percentage of Participants Who Experienced Laboratory Abnormalities
Query!
Assessment method [6]
0
0
Treatment-emergent laboratory abnormalities for Blinded Treatment phase are defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of Blinded Treatment phase study drug plus 30 days for participants who permanently discontinued Blinded Treatment phase study drug or before the first dose of Open-label Treatment phase study drug. For the Open-label Treatment phase, treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from Open-label baseline at any postbaseline time point, up to and including the date of last dose of Open-label Treatment phase study drug plus 30 days for participants who permanently discontinued Open-label phase study drug. For maximum postbaseline toxicity grade, the most severe graded abnormality from all tests was counted for each patient. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening.
Query!
Timepoint [6]
0
0
Blinded Treatment phase: First dose date up to 50.6 weeks plus 30 days; Open-label phase: First dose date up to 50.7 weeks plus 30 days
Query!
Eligibility
Key inclusion criteria
Key
- Males, or non-pregnant, non-lactating females, at least 18 years of age based on the
date of the screening visit.
- UC of at least 3 months duration before randomization confirmed by endoscopy and
histology at any time in the past AND a minimum disease extent of 15 centimeter (cm)
from the anal verge. Documentation of endoscopy and histology consistent with the
diagnosis of UC must be available in the source documents prior to the initiation of
screening.
- Moderately to severely active UC as determined during screening by a centrally read
endoscopy score = 2, a Rectal Bleeding subscore = 1, a Stool Frequency subscore = 1
and Physicians Global Assessment (PGA) of = 2 as defined by the Mayo Clinic Score;
total MCS must be between 6 and 12, inclusive.
- Previously demonstrated an inadequate response (primary non-response) or loss of
response (secondary non-response) to a tumor necrosis factor-alpha (TNFa) inhibitor
(ie, infliximab, adalimumab, golimumab, or biosimilars). The induction treatment
regimen resulting in inadequate response or loss of response should have been in
accordance with local prescribing information/guidelines or as outlined below.
- Infliximab: 5 mg/kg at Weeks 0, 2, and 6
- Adalimumab: 160 mg on Day 1 (given in 1 day or split over consecutive days),
followed by 80 mg 2 weeks later (Day 15), 40 mg 2 weeks later (Day 29) and every
2 weeks thereafter until Day 57
- Golimumab: 200 mg on Day 1 followed by 100 mg at Week 2
- May be receiving concomitant therapy for UC at the time of enrollment as specified in
the protocol, provided the dose prescribed has been stable as indicated prior to
randomization.
- Meet the following Tuberculosis (TB) screening criteria:
- No evidence of active TB, latent TB, or inadequately treated TB as evidenced by 1
of the following:
- A negative QuantiFERON test or equivalent assay reported by the central lab
at screening or within 90 days prior to randomization date. OR
- A history of fully treated active or latent TB according to local standard
of care. Investigator must verify adequate previous anti-TB treatment and
provide documentation; these individuals do not require QuantiFERON testing
and eligibility must be approved by the sponsor prior to enrollment in the
study. AND
- A chest radiograph (views as per local guidelines with the report or films
available for investigator review) taken at screening or within the 4 months
prior to randomization without evidence of active or latent TB infection.
- Laboratory assessments at screening within the following parameters:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and total
bilirubin = 2 X upper limit of normal (ULN)
- Estimated glomerular filtration rate (eGFR) = 60 ml/min (1.0 mL/sec) as
calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
Cystatin C formula as described in protocol.
- Hemoglobin = 8 g/dL (= 80 g/L)
- Absolute neutrophil count (ANC) = 1.5 × 10^3/µL (= 1.5 GI/L)
- Platelets = 100 × 10^3/µL (= 100 GI/L)
- White blood cells (WBC) = 3 × 10^3/µL (= 3 GI/L)
- Absolute lymphocyte count = 0.75 × 10^3/µL (= 0.75 GI/L)
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Currently displaying clinical signs of acute severe colitis, fulminant colitis, or
toxic megacolon.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/12/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/12/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
19
Query!
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Coastal Digestive Health - Maroochydore
Query!
Recruitment hospital [2]
0
0
The Queen Elizabeth Hospital - Woodville
Query!
Recruitment hospital [3]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [4]
0
0
Emeritus Research - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
4558 - Maroochydore
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville
Query!
Recruitment postcode(s) [3]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [4]
0
0
3124 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Louisiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nevada
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
South Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Wisconsin
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Innsbruck
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Vienna
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
British Columbia
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Clichy
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Dijon
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Grenoble
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Lille
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Pierre-Benite
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Rennes
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Saint-Etienne
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Toulouse
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Vandoeuvre-les-Nancy Cedex
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Kiel
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Leipzig
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Minden
Query!
Country [28]
0
0
Italy
Query!
State/province [28]
0
0
Rozzano
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Szczecin
Query!
Country [30]
0
0
Poland
Query!
State/province [30]
0
0
Torun
Query!
Country [31]
0
0
Poland
Query!
State/province [31]
0
0
Wroclaw
Query!
Country [32]
0
0
Switzerland
Query!
State/province [32]
0
0
Bern
Query!
Country [33]
0
0
Switzerland
Query!
State/province [33]
0
0
Zurich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to demonstrate the efficacy of tilpisertib (formerly
GS-4875) compared with placebo control in achieving clinical remission per modified Mayo
Clinic Score (MCS) in adults with moderately to severely active ulcerative colitis (UC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04130919
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04130919
Download to PDF